欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01477 欧康维视生物-B

休市中 03-27 16:08:20

7.330

+0.370

+5.32%

最高7.400	最低6.960	成交量145.59万
今开7.000	昨收6.960	日振幅6.32%
总市值59.74亿	流通市值59.74亿	总股本8.15亿
成交额1,057万	换手率0.18%	流通股本8.15亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01477","market":"HK","secType":"STK","nameCN":"欧康维视生物-B","latestPrice":7.33,"timestamp":1774598900002,"preClose":6.96,"halted":0,"volume":1455893,"delay":0,"changeRate":0.0531609195402299,"floatShares":815000000,"shares":815000000,"eps":-0.392324,"marketStatus":"休市中","change":0.37,"latestTime":"03-27 16:08:20","open":7,"high":7.4,"low":6.96,"amount":10565050,"amplitude":0.063218,"askPrice":7.34,"askSize":16500,"bidPrice":7.33,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.335,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774834200000},"marketStatusCode":7,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":6.96,"openAndCloseTimeList":[[1774575000000,1774584000000],[1774587600000,1774598400000]],"volumeRatio":2.55913693082935,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01477","defaultTab":"news","newsList":[{"id":"2622260578","title":"美国FDA批准首款致命儿童罕见病疗法，火箭制药股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2622260578","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622260578?lang=zh_cn&edition=full","pubTime":"2026-03-27 20:06","pubTimestamp":1774613160,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局批准火箭制药一款针对儿童罕见且通常致命的免疫缺陷疾病的基因疗法后，该公司股价在周五盘前大涨 10%。这是该病症首次获得监管机构的治疗批准。　　此前，尚无 FDA 专门批准用于治疗该疾病的药物。　　FDA 依据一项衡量免疫细胞功能改善的替代终点，授予该药物加速批准资格。　　但普拉萨德周四表示，FDA 在审评罕见病疗法时 “持续采取较大的监管灵活性”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-03-27/doc-inhsmtim9451054.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","BK4585","BK4588","LABU","BK1574"],"gpt_icon":0},{"id":"2622845105","title":"诺华制药(NVS.US)20亿美元收购Excellergy 加码食物过敏与免疫疾病赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845105","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622845105?lang=zh_cn&edition=full","pubTime":"2026-03-27 15:36","pubTimestamp":1774597007,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，诺华制药已同意以高达20亿美元的价格收购生物技术公司Excellergy Inc.，此项交易将强化其在食物过敏及其他免疫疾病治疗领域的产品组合。此次收购的核心资产是Excellergy公司研发的创新候选药物Exl-111。从行业影响来看，Excellergy的加入将使诺华制药在过敏性疾病领域拥有更具差异化的产品组合。此外，诺华制药还于去年10月宣布了其最大规模投资之一——以120亿美元收购Avidity Biosciences公司，随后又陆续达成多项针对过敏性疾病及乳腺癌药物的交易合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420347.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK4578","NVS","LU0211331839.USD","LU0070302665.USD","IE00B2B36J28.USD","01477","BK4532","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","BK4585","IE00BJJMRZ35.SGD","LU0320765489.SGD","LU0208291251.USD","BK4588","IE0002141913.USD","BK4007","BK1574","IE00B4R5TH58.HKD"],"gpt_icon":0},{"id":"2622814754","title":"知名药企IPO关键期，被曝销售行贿，一款药撑起公司超99%收入","url":"https://stock-news.laohu8.com/highlight/detail?id=2622814754","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622814754?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:25","pubTimestamp":1774585500,"startTime":"0","endTime":"0","summary":"　　医药反腐风暴下，又一拟上市企业卷入商业贿赂漩涡。　　3月24日，国家医保局通报“张某猛药品销售行贿案”，而众多涉案细节，指向药品复方黄柏液涂剂的独家生产企业，正处于赴港IPO关键期的山东汉方制药股份有限公司。2024年11月，张某猛因行贿罪和对非国家工作人员行贿罪，被判处有期徒刑一年、缓刑一年半，并处罚金2万元。汉方制药在IPO关键期遭遇行贿案冲击，再次凸显了医药企业规范经营的重要性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/newstock/2026-03-27/doc-inhsmamz8378246.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/newstock/2026-03-27/doc-inhsmamz8378246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","01477","BK1574"],"gpt_icon":0},{"id":"1113298093","title":"异动解读 | 业绩强劲亏损大幅收窄，欧康维视生物-B盘中大涨5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1113298093","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113298093?lang=zh_cn&edition=full","pubTime":"2026-03-27 11:55","pubTimestamp":1774583723,"startTime":"0","endTime":"0","summary":"欧康维视生物-B今日盘中股价大幅上涨5.17%，市场表现引人注目。消息面上，公司于近期发布了截至2025年12月31日止年度的业绩报告。报告显示，公司实现收益约8.04亿元人民币，同比大幅增长92.7%。年内净亏损为1.59亿元，较上年同期显著收窄40.8%。此外，公司同日宣布了董事会成员变更，建议委任庄蓓蓓女士为新的独立非执行董事。这一系列积极的财务数据和公司治理动态，共同增强了投资者对公司未来发展的信心，成为推动股价上涨的主要动力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["01477"],"gpt_icon":0},{"id":"2622976458","title":"家族控股特点鲜明 亲属企业获取亿元推广费 汉方制药关联交易与巨额分红引关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2622976458","media":"滚动播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622976458?lang=zh_cn&edition=full","pubTime":"2026-03-27 03:48","pubTimestamp":1774554480,"startTime":"0","endTime":"0","summary":"　　作为一家赴港上市中药企业，山东汉方制药股份有限公司的招股书显现鲜明的家族企业特质。招股书显示，目前汉方制药由秦文基、秦银基兄弟100%控股，管理层存在多位家族成员，董事长外甥控制的企业曾作为关联方长期获取巨额推广费，且在上市前进行了数额可观的现金分红。这些信息勾勒出公司的经营治理架构，引发了市场对其决策独立性、关联交易公允性及长期发展可持续性的关注。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-27/doc-inhskfhc9844570.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK4585","BK4588","BK1191","VIG"],"gpt_icon":0},{"id":"2622867591","title":"交易额最高9475万美元！英硅智能上市不到3个月，宣布第4笔国内AI制药合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2622867591","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622867591?lang=zh_cn&edition=full","pubTime":"2026-03-27 00:31","pubTimestamp":1774542710,"startTime":"0","endTime":"0","summary":"中国AI（人工智能）制药领域迎来一笔新合作。3月26日，英硅智能（HK03696，股价50.30港元，市值287.92亿港元）公告称，在过去一年良好的合作关系基础上，公司与元羿生物已达成一项扩展的AI驱动研发合作。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603273686033797.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603273686033797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","CHAT","AIPO","AGIX","01477","BK1191"],"gpt_icon":0},{"id":"2622786408","title":"欧康维视生物-B(01477)：建议委任庄蓓蓓为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2622786408","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622786408?lang=zh_cn&edition=full","pubTime":"2026-03-26 23:47","pubTimestamp":1774540074,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，胡定旭先生于服务超过五年后，将根据公司的公司章程细则于公司应届股东周年大会上退任。胡先生已告知董事会，彼决定不于股东周年大会上膺选连任，以投入更多时间处理其他事务。鉴于胡先生即将退任，于2026年3月26日，董事会议决将于股东周年大会上建议委任庄蓓蓓女士为独立非执行董事，以填补胡先生退任后的董事会空缺，自股东周年大会结束起生效，惟须待股东批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420052.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2622486429","title":"欧康维视生物-B(01477)发布年度业绩，净亏损1.59亿元 同比减少40.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622486429","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622486429?lang=zh_cn&edition=full","pubTime":"2026-03-26 23:45","pubTimestamp":1774539902,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布截至2025年12月31日止年度业绩，该集团取得收益8.04亿元，同比增加92.75%;年内亏损1.59亿元，同比减少40.8%;每股亏损0.2元。公司进一步拓展院内市场，主要产品销量保持稳定增长。博优景 获NMPA批准上市，用于治疗成人新生血管(湿性)年龄相关性黄斑变性及糖尿病黄斑水肿，这标志着公司在眼底疾病领域又一重要产品的诞生。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"1192206229","title":"欧康维视生物-B营收大增92.7%，亏损幅度同期显著收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1192206229","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192206229?lang=zh_cn&edition=full","pubTime":"2026-03-26 22:56","pubTimestamp":1774536981,"startTime":"0","endTime":"0","summary":"欧康维视生物-B于截至2025年12月31日止年度，录得收入约人民币8.04亿元，同比增长92.7%。综合毛利约人民币3.61亿元，增幅达60.4%，毛利率约44.9%。报告期内年内亏损约人民币1.59亿元，较上年有所减少。报告期末，集团资产总值约人民币40.91亿元，其中非流动资产约人民币31.40亿元，流动资产约人民币9.51亿元。报告期内并无重大或然负债、承诺及诉讼。报告期末未有建议派付任何股息。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477"],"gpt_icon":0},{"id":"2622783996","title":"“AI制药”的晶泰控股扭亏虚与实","url":"https://stock-news.laohu8.com/highlight/detail?id=2622783996","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622783996?lang=zh_cn&edition=full","pubTime":"2026-03-26 14:52","pubTimestamp":1774507932,"startTime":"0","endTime":"0","summary":"港股“AI制药明星企业”晶泰控股交出了上市以来的首份扭亏答卷。\n2025年，晶泰控股实现营业收入8....","market":"sh","thumbnail":"https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/abf9f2b56caccf2c92db82642df48d35"],"rights":{"source":null,"url":"https://wallstreetcn.com/articles/3768447","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3768447","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"“AI制药”的晶泰控股扭亏虚与实","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1141","01477","02228","BK1574","BK1617","AGIX","CHAT","BK1191","AIPO"],"gpt_icon":0},{"id":"2622021631","title":"健帆生物：健福制药为公司持股10%的参股子公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2622021631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622021631?lang=zh_cn&edition=full","pubTime":"2026-03-25 17:27","pubTimestamp":1774430829,"startTime":"0","endTime":"0","summary":"证券之星消息，健帆生物03月25日在投资者关系平台上答复投资者关心的问题。有没有收购成为全资子公司的想法？健福制药为公司持股10%的参股子公司。目前暂无相关收购计划。健帆医疗器械产业项目二期已于2026年1月奠基动工，预计2027年下半年建成。公司对外投资及项目建设进展等情况，公司将根据规定及时履行信息披露义务，敬请关注公司公告动态。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032500033140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0251","BK1574","300529","BK1191"],"gpt_icon":0},{"id":"2621964280","title":"长寿制药公司 Enlivex 获 2100 万美元债务融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2621964280","media":"链捕手","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621964280?lang=zh_cn&edition=full","pubTime":"2026-03-24 22:57","pubTimestamp":1774364278,"startTime":"0","endTime":"0","summary":" ChainCatcher 消息，据市场消息，长寿医药及 RAIN 代币资产库 Enlivex 宣布获得纽约机构基金 The Lind Partners 提供的 2100 万美元债务融资。公司称将继续执行其预测市场代币资产库策略，新增约 30 亿枚 RAIN 代币，并用于支持公司运营计划。Enlivex 为纳斯达克上市公司，正在开发治疗骨关节炎等关节疾病的疗法，同时作为 RAIN 数字资产库持有大规模 RAIN 头寸。RAIN 为部署在 Arbitrum 网络上的去中心化预测市场协议代币，其协议通过 AI 判定结果并采用回购销毁机制。Enlivex 股价当前约为 1.05 美元，日内下跌约 5%。 ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.chaincatcher.com/article/2254180","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1191","BK1574"],"gpt_icon":0},{"id":"2621378290","title":"千红制药：截至当前公司尚未收到方圆制药项目的管辖法院出具的公开裁定文书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621378290","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621378290?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:33","pubTimestamp":1774323217,"startTime":"0","endTime":"0","summary":"证券之星消息，千红制药(002550)03月23日在投资者关系平台上答复投资者关心的问题。投资者提问：方圆制药事实上已经到了破产清算状态，这么重大的事项公司都没有及时按照法律法规发布公告，是不是要追究相关人员法律责任并赔偿股票投资者的损失？千红制药回复：尊敬的投资者，您好，截至当前，公司尚未收到方圆制药项目的管辖法院出具的公开裁定文书。公司严格按照相关法律法规履行信息披露义务，不存在应披露未披露的重大事项。感谢您对公司的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400016093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["01477","BK0239","BK1191","BK1574","002550"],"gpt_icon":0},{"id":"2621018032","title":"重磅合作频现，AI制药重构药物研发产业格局","url":"https://stock-news.laohu8.com/highlight/detail?id=2621018032","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621018032?lang=zh_cn&edition=full","pubTime":"2026-03-24 11:16","pubTimestamp":1774322160,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者闫硕2026年以来，全球人工智能（AI）制药领域合作浪潮持续涌动，产学研、中外药企间的协同创新案例密集落地，人工智能与生物医药的融合正进入规模化应用阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603243682235017.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682235017.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01477","BK1574","BK1191"],"gpt_icon":0},{"id":"2621329776","title":"山东新华制药股份(00719)：新达制药获得布洛芬颗粒药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2621329776","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621329776?lang=zh_cn&edition=full","pubTime":"2026-03-23 16:41","pubTimestamp":1774255302,"startTime":"0","endTime":"0","summary":"智通财经APP讯，山东新华制药股份 发布公告，近日，山东新华制药股份有限公司之全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的布洛芬颗粒《药品注册证书》。2023年12月，新达制药向国家药品监督管理局药品审评中心递交布洛芬颗粒上市许可注册申报资料并获受理，2026年3月获得《药品注册证书》，审评结论为批准注册。布洛芬颗粒是《国家基本医疗保险、工伤保险和生育保险药品目录》乙类品种。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417348.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","00719","01477","BK1515","BK1574"],"gpt_icon":0},{"id":"2621175723","title":"港股异动 | 佳兆业健康(00876)逆市涨超40% 公司拟收购青海制药控股权 拿下稀缺麻精牌照","url":"https://stock-news.laohu8.com/highlight/detail?id=2621175723","media":"智通财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621175723?lang=zh_cn&edition=full","pubTime":"2026-03-23 10:17","pubTimestamp":1774232232,"startTime":"0","endTime":"0","summary":"佳兆业健康(00876)逆市涨超40%，截至发稿，涨30%，报0.117港元，成交额496.96万港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260323/20260323101803_45229.png?x-oss-process=image/format,jpg/quality,q_60","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260323/20260323101803_45229.png?x-oss-process=image/format,jpg/quality,q_60"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417183.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["00876","BK1191","01477","VXUS","BK1222","BK4588","BK4585","BK1574"],"gpt_icon":0},{"id":"2620073588","title":"AI制药忙“圈钱”，资本估值掐尖，兑现期已至可盈利要等多久？","url":"https://stock-news.laohu8.com/highlight/detail?id=2620073588","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620073588?lang=zh_cn&edition=full","pubTime":"2026-03-20 19:14","pubTimestamp":1774005240,"startTime":"0","endTime":"0","summary":"除百图生科外，另有多家AI制药企业被传出港交所上市计划。据悉，“AI+递送平台”剂泰医药正考虑赴港IPO，募资规模约2亿美元。资本的热浪，正在让AI制药赛道持续升温。早期阶段，AI制药企业估值主要依赖技术平台的颠覆性。对于排队上市的AI制药企业而言，当前窗口期应构建“技术+管线+生态”三维叙事策略，平衡科技属性与生物医药属性，以吸引多元化长线资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-20/doc-inhrrvnu0708499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1574","01477"],"gpt_icon":0},{"id":"2620066342","title":"齐鲁制药创新药QLH2405注射液获批临床，瞄准阿尔茨海默病早期干预","url":"https://stock-news.laohu8.com/highlight/detail?id=2620066342","media":"蓝鲸财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620066342?lang=zh_cn&edition=full","pubTime":"2026-03-20 10:24","pubTimestamp":1773973496,"startTime":"0","endTime":"0","summary":"3月13日，据国家药品监督管理局药品审评中心官网显示，齐鲁制药自主研发的1类新药QLH2405注射液获得临床试验默示许可，拟定适应症为阿尔茨海默病源性轻度认知障碍和轻度阿尔茨海默病。作为一种慢性、进行性神经退行性疾病，阿尔茨海默病起病隐匿且早期干预窗口极为关键。获批临床后，齐鲁制药将继续秉持科学、严谨、规范的原则，加快推进临床试验，力争全面评估QLH2405注射液在目标人群中的安全性及有效性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773973135107607202","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1574","BK1161","159992","BK1191","01477","06978"],"gpt_icon":0},{"id":"2620295751","title":"AI制药打响算力竞赛：罗氏布局AI工厂 行业痛点仍存","url":"https://stock-news.laohu8.com/highlight/detail?id=2620295751","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620295751?lang=zh_cn&edition=full","pubTime":"2026-03-19 07:07","pubTimestamp":1773875243,"startTime":"0","endTime":"0","summary":"【AI制药打响算力竞赛：罗氏布局AI工厂 行业痛点仍存】当外界还在争论AI究竟只是药物研发的“辅助工具”还是能颠覆整个产业时，全球制药巨头们已经用真金白银做出了选择。3月16日，罗氏宣布扩展其全球人工智能基础设施，正式部署由英伟达最新一代加速计算技术驱动的“人工智能工厂”。此次在美国和欧洲完成了2176个高性能GPU的部署，使其本地和云端GPU基础设施总容量超过3500个Blackwell GPU。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603193676448278.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603193676448278.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1191","01477"],"gpt_icon":0},{"id":"2620574792","title":"佳兆业集团(01638)拟出售青海制药30.121%实际权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2620574792","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620574792?lang=zh_cn&edition=full","pubTime":"2026-03-18 22:40","pubTimestamp":1773844858,"startTime":"0","endTime":"0","summary":"于完成时，佳兆业健康将透过目标公司持有项目公司的54.84%股权。于该协议日期，公司于佳兆业健康约42.99%的已发行股份总数中拥有权益。于该交易完成后，公司于佳兆业健康的权益将增加约1.53%至约44.52%，而佳兆业健康将继续入账列为公司的附属公司。因此，公司于该协议日期在项目公司的实际持股权益为54.2916%，而于该交易完成后，公司于项目公司的实际持股权益将为24.1706%，导致公司出售项目公司30.1210%的实际权益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415650.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1507","BK1191","BK1582","01477","01638","BK1555","BK1240"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ocumension.com","stockEarnings":[{"period":"1week","weight":0.0562},{"period":"1month","weight":0.0152},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.1006},{"period":"1year","weight":0.4898},{"period":"ytd","weight":-0.0095}],"compareEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":-0.0678},{"period":"3month","weight":-0.0336},{"period":"6month","weight":-0.045},{"period":"1year","weight":0.0582},{"period":"ytd","weight":-0.0265}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"欧康维视生物是一家主要从事眼科药物的研发和商业化的公司。该公司产品主要包括OT-401“优施莹”氟轻松玻璃体内植入剂、OT-702“博优景”阿柏西普眼内注射溶液、OT-402“维速达尔”注射用维替泊芬、OT-204“欧沁”玻璃酸钠滴眼液及OT-305“贝特舒”盐酸倍他洛尔滴眼液等。该公司产品主要用于治疗葡萄膜炎、眼底疾病、屈光矫正、干眼症（DED）、青光眼及角结膜炎等各种眼前及眼后段疾病。该公司主要在中国国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.166667,"avgChangeRate":-0.097698},{"month":2,"riseRate":0.5,"avgChangeRate":-0.037557},{"month":3,"riseRate":0.5,"avgChangeRate":0.043784},{"month":4,"riseRate":0.4,"avgChangeRate":0.017956},{"month":5,"riseRate":0.6,"avgChangeRate":0.137077},{"month":6,"riseRate":0.8,"avgChangeRate":0.129408},{"month":7,"riseRate":0.4,"avgChangeRate":-0.027707},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.064893},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.082685},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.121217},{"month":11,"riseRate":0.333333,"avgChangeRate":0.004503},{"month":12,"riseRate":0.5,"avgChangeRate":0.058088}],"exchange":"SEHK","name":"欧康维视生物-B","nameEN":"OCUMENSION-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"欧康维视生物-B,01477,欧康维视生物-B股票,欧康维视生物-B股票老虎,欧康维视生物-B股票老虎国际,欧康维视生物-B行情,欧康维视生物-B股票行情,欧康维视生物-B股价,欧康维视生物-B股市,欧康维视生物-B股票价格,欧康维视生物-B股票交易,欧康维视生物-B股票购买,欧康维视生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"欧康维视生物-B(01477)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供欧康维视生物-B(01477)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}